Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.50 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.45 |
| ▸ | STAT6 | P42226 | 1/20 | 0.44 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.43 |
| ▸ | PIK3CA | P42336 | 3/20 | 0.43 |
| ▸ | PIK3CB | P42338 | 3/20 | 0.43 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.42 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.42 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL826316 | 0.91 | RXFP1 (0.42) | RXFP1MAPK8STAT6SLC2A1EGLN1 | |
| SCHEMBL823396 | 0.87 | L3MBTL1 (0.47) | KDM4ESMN1; SMN2EGLN1ALDH1A1 | |
| SCHEMBL823382 | 0.85 | ERCC1 (0.45) | SLC2A1EGLN1KMT2AMEN1CYP3A4 | |
| SCHEMBL823378 | 0.85 | SLC2A1 (0.52) | RXFP1SLC2A1KDM4ESMN1; SMN2EGLN1 | |
| SCHEMBL823395 | 0.81 | CYP2C9 (0.51) | STAT6KDM4ESMN1; SMN2EGLN1ALDH1A1 | |
| SCHEMBL823331 | 0.79 | THRB (0.51) | KDM4ESMN1; SMN2EGLN1ALDH1A1KMT2A | |
| SCHEMBL823339 | 0.77 | WDR5 (0.47) | CYP3A4CYP2C19 | |
| SCHEMBL12952918 | 0.77 | SLC2A1 (0.46) | SLC2A1KDM4ESMN1; SMN2PIK3CAPIK3CB | |
| SCHEMBL823327 | 0.76 | MAPT (0.48) | RXFP1SLC2A1KDM4ESMN1; SMN2PIK3CA | |
| SCHEMBL823390 | 0.75 | CNR1 (0.42) | EGLN1PIK3CBKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8859563-B2 | Bicyclic pyrimidinones and uses thereof | AVEXA LIMITED (AU) | 2014-10-14 | — | — | US | disclosed |
| US-20120232035-A1 | Bicyclic pyrimidinones and uses thereof | AVEXA LIMITED (AU) | 2012-09-13 | — | — | US | disclosed |
| US-20120232035-A1 | Bicyclic pyrimidinones and uses thereof | AVEXA LIMITED (AU) | 2012-09-13 | — | — | US | disclosed |
| US-8207334-B2 | Bicyclic pyrimidinones and uses thereof | AVEXA LIMITED (AU) | 2012-06-26 | — | — | US | disclosed |
| US-8207334-B2 | Bicyclic pyrimidinones and uses thereof | AVEXA LIMITED (AU) | 2012-06-26 | — | — | US | disclosed |
| US-8143268-B2 | Bicyclic pyrimidinones and uses thereof | AVEXA LIMITED (AU) | 2012-03-27 | — | — | US | disclosed |
| US-8143268-B2 | Bicyclic pyrimidinones and uses thereof | AVEXA LIMITED (AU) | 2012-03-27 | — | — | US | disclosed |
| US-8143268-B2 | Bicyclic pyrimidinones and uses thereof | AVEXA LIMITED (AU) | 2012-03-27 | — | — | US | disclosed |
| EP-2114903-B1 | BICYCLIC PYRIMIDINONES AND USES THEREOF | AVEXA LTD (AU) | 2011-01-26 | — | — | EP | disclosed |
| EP-2114903-B1 | BICYCLIC PYRIMIDINONES AND USES THEREOF | AVEXA LTD (AU) | 2011-01-26 | — | — | EP | disclosed |
| US-20110009366-A1 | BICYCLIC PYRIMIDINONES AND USES THEREOF | AVEXA LIMITED (AU) | 2011-01-13 | — | — | US | disclosed |
| US-20110009366-A1 | BICYCLIC PYRIMIDINONES AND USES THEREOF | AVEXA LIMITED (AU) | 2011-01-13 | — | — | US | disclosed |
| EP-2269992-A1 | Bicyclic pyrimidinones for the treatment of viral infections | Avexa Limited (AU) | 2011-01-05 | — | — | EP | disclosed |
| EP-2269992-A1 | Bicyclic pyrimidinones for the treatment of viral infections | Avexa Limited (AU) | 2011-01-05 | — | — | EP | disclosed |
| US-20100168063-A1 | BICYCLIC PYRIMIDINONES AND USES THEREOF | AVEXA LIMITED (AU) | 2010-07-01 | — | — | US | disclosed |
| US-20100168063-A1 | BICYCLIC PYRIMIDINONES AND USES THEREOF | AVEXA LIMITED (AU) | 2010-07-01 | — | — | US | disclosed |
| US-20100168063-A1 | BICYCLIC PYRIMIDINONES AND USES THEREOF | AVEXA LIMITED (AU) | 2010-07-01 | — | — | US | disclosed |
| WO-2008077188-A1 | BICYCLIC PYRIMIDINONES AND USES THEREOF | AVEXA LIMITED (AU) | 2008-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100168063-A1 | BICYCLIC PYRIMIDINONES AND USES THEREOF | TPMT, TYMP, DPYD | RXFP1 3746/4885MAPK8 1624/4885STAT6 408/4885 |
| US-20120232035-A1 | Bicyclic pyrimidinones and uses thereof | TPMT, TYMP, DPYD | RXFP1 3746/4885MAPK8 1624/4885STAT6 408/4885 |
| US-20110009366-A1 | BICYCLIC PYRIMIDINONES AND USES THEREOF | TPMT, TYMP, DPYD | RXFP1 3746/4885MAPK8 1624/4885STAT6 408/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.